Adeno-associated virus explained

Adeno-associated viruses (AAV) are small viruses that infect humans and some other primate species. They belong to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae. They are small (approximately 26 nm in diameter) replication-defective, nonenveloped viruses and have linear single-stranded DNA (ssDNA) genome of approximately 4.8 kilobases (kb).[1] [2]

Several features make AAV an attractive candidate for creating viral vectors for gene therapy, and for the creation of isogenic human disease models.[3] Gene therapy vectors using AAV can infect both dividing and quiescent cells and persist in an extrachromosomal state without integrating into the genome of the host cell. In the native virus, however, integration of virally carried genes into the host genome does occur.[4] Integration can be important for certain applications, but can also have unwanted consequences. Recent human clinical trials using AAV for gene therapy in the retina have shown promise.[5]

In March 2023, a series of Nature papers detected high titres of adeno-associated virus 2 (AAV2), alongside adenovirus and herpesvirus, in samples from a wave of childhood hepatitis.[6] One paper suggested that AAV2 co-infection may contribute to more serious liver disease than infection with only adeno- or herpesviruses and that the causal link remains to be established.[7]

History

The adeno-associated virus (AAV), previously thought to be a contaminant in adenovirus preparations, was first identified as a dependoparvovirus in the 1960s in the laboratories of Bob Atchison at Pittsburgh and Wallace Rowe at NIH. Serological studies in humans subsequently indicated that, despite being present in people infected by helper viruses such as adenovirus or herpes virus, AAV itself did not cause any disease.[8]

Use in gene therapy

Advantages and drawbacks

Wild-type AAV has attracted considerable interest from gene therapy researchers due to a number of features. Chief amongst these was the virus's apparent lack of pathogenicity. It can also infect non-dividing cells and has the ability to stably integrate into the host cell genome at a specific site (designated AAVS1) in the human chromosome 19.[9] [10] This feature makes it somewhat more predictable than retroviruses, which present the threat of a random insertion and of mutagenesis, which is sometimes followed by development of a cancer. The AAV genome integrates most frequently into the site mentioned, while random incorporations into the genome take place with a negligible frequency. Development of AAVs as gene therapy vectors, however, has eliminated this integrative capacity by removal of the rep and cap from the DNA of the vector. The desired gene together with a promoter to drive transcription of the gene is inserted between the inverted terminal repeats (ITRs) that aid in concatemer formation in the nucleus after the single-stranded vector DNA is converted by host cell DNA polymerase complexes into double-stranded DNA. AAV-based gene therapy vectors form episomal concatemers in the host cell nucleus. In non-dividing cells, these concatemers remain intact for the life of the host cell. In dividing cells, AAV DNA is lost through cell division, since the episomal DNA is not replicated along with the host cell DNA.[11] Random integration of AAV DNA into the host genome is detectable but occurs at very low frequency. AAVs also present very low immunogenicity, seemingly restricted to generation of neutralizing antibodies, while they induce no clearly defined cytotoxic response.[12] [13] [14] This feature, along with the ability to infect quiescent cells present their dominance over adenoviruses as vectors for human gene therapy.

Use of the virus does present some disadvantages. The cloning capacity of the vector is relatively limited and most therapeutic genes require the complete replacement of the virus's 4.8 kilobase genome. Large genes are, therefore, not suitable for use in a standard AAV vector. Options are currently being explored to overcome the limited coding capacity.[15] The AAV ITRs of two genomes can anneal to form head-to-tail concatemers, almost doubling the capacity of the vector. Insertion of splice sites allows for the removal of the ITRs from the transcript.

Because of AAV's specialized gene therapy advantages, researchers have created an altered version of AAV termed self-complementary adeno-associated virus (scAAV). Whereas AAV packages a single strand of DNA and must wait for its second strand to be synthesized, scAAV packages two shorter strands that are complementary to each other. By avoiding second-strand synthesis, scAAV can express more quickly, although as a caveat, scAAV can only encode half of the already limited capacity of AAV.[16] Recent reports suggest that scAAV vectors are more immunogenic than single stranded adenovirus vectors, inducing a stronger activation of cytotoxic T lymphocytes.[17]

Humoral immunity instigated by infection with the wild type is thought to be common. The associated neutralising activity limits the usefulness of the most commonly used serotype AAV2 in certain applications. Accordingly, the majority of clinical trials under way involve delivery of AAV2 into the brain, a relatively immunologically privileged organ. In the brain, AAV2 is strongly neuron-specific.

Clinical trials

As of 2019, AAV vectors have been used in over 250 clinical trials worldwide, approximately 8.3% of virus-vectored gene-therapy trials.[18] Recently, promising results have been obtained from Phase 1 and Phase 2 trials for a number of diseases, including Leber's congenital amaurosis,[5] [19] [20] hemophilia,[21] congestive heart failure,[22] spinal muscular atrophy,[23] lipoprotein lipase deficiency,[24] and Parkinson's disease.[25]

Selected clinical trials using AAV-based vectors[26]
Indication Gene Route of administration Phase Subject number Status
CFTR Lung, via aerosol I 12 Complete
CFTRLung, via aerosol II 38 Complete
CFTR Lung, via aerosol II 100 Complete
FIX Intramuscular I 9 Complete
FIX Hepatic artery I 6 Ended
TNFR:Fc Intraarticular I 1 Ongoing
AAT Intramuscular I 12 Ongoing
RPE65 Subretinal I–II Multiple Several ongoing and complete (voretigene neparvovec)
sFlt-1 Subretinal I–II 24 Ongoing
SGCA Intramuscular I 10 Ongoing
GAD65, GAD67 Intracranial I 12 Complete[27]
AAC Intracranial I 21 Ongoing
CLN2 Intracranial I 10 Ongoing
NGF Intracranial I 6 Ongoing
SMN1 Intravenous, intrathecalI–III 150+ Several ongoing and complete (onasemnogene abeparvovec)
SERCA2a Intra-coronary IIb 250 Ongoing

Fundamental biology

Genomics, transcriptomics and proteomics

The AAV genome is built of single-stranded deoxyribonucleic acid (ssDNA), either positive- or negative-sensed, which is about 4.7 kilobase long. The genome comprises ITRs at both ends of the DNA strand, and two open reading frames (ORFs): rep and cap. The former is composed of four overlapping genes encoding Rep proteins required for the AAV life cycle, and the latter contains overlapping nucleotide sequences of capsid proteins: VP1, VP2 and VP3, which interact to form a capsid with icosahedral symmetry.[28]

ITR sequences

The inverted terminal repeat (ITR) sequences comprise 145 bases each. They were named so because of their symmetry, which was shown to be required for efficient multiplication of the AAV genome.[29] The feature of these sequences that gives them this property is their ability to form a hairpin, which contributes to so-called self-priming that allows primase-independent synthesis of the second DNA strand. The ITRs were also shown to be required for both integration of the AAV DNA into the host cell genome (19th chromosome in humans) and rescue from it,[30] [31] as well as for efficient encapsidation of the AAV DNA combined with generation of a fully assembled, deoxyribonuclease-resistant AAV particles.[32]

With regard to gene therapy, ITRs seem to be the only sequences required in cis next to the therapeutic gene: structural (cap) and packaging (rep) proteins can be delivered in trans. With this assumption many methods were established for efficient production of recombinant AAV (rAAV) vectors containing a reporter or therapeutic gene. However, it was also published that the ITRs are not the only elements required in cis for the effective replication and encapsidation. A few research groups have identified a sequence designated cis-acting Rep-dependent element (CARE) inside the coding sequence of the rep gene. CARE was shown to augment the replication and encapsidation when present in cis.[33] [34] [35] [36]

rep gene and Rep proteins

On the "left side" of the genome there are two promoters called p5 and p19, from which two overlapping messenger ribonucleic acids (mRNAs) of different length can be produced. Each of these contains an intron which can be either spliced out or not. Given these possibilities, four various mRNAs, and consequently four various Rep proteins with overlapping sequence can be synthesized. Their names depict their sizes in kilodaltons (kDa): Rep78, Rep68, Rep52 and Rep40.[37] Rep78 and 68 can specifically bind the hairpin formed by the ITR in the self-priming act and cleave at a specific region, designated terminal resolution site, within the hairpin. They were also shown to be necessary for the AAVS1-specific integration of the AAV genome. All four Rep proteins were shown to bind ATP and to possess helicase activity. It was also shown that they upregulate the transcription from the p40 promoter (mentioned below), but downregulate both p5 and p19 promoters.[31] [37] [38] [39] [40] [41]

cap gene and VP proteins

The right side of a positive-sensed AAV genome encodes overlapping sequences of three capsid proteins, VP1, VP2 and VP3, and two accessory proteins, MAAP & AAP, which start from one promoter, designated p40. The molecular weights of these proteins are 87, 72 and 62 kiloDaltons, respectively.[42] The AAV capsid is composed of a mixture of VP1, VP2, and VP3 totaling 60 monomers arranged in icosahedral symmetry in a ratio of 1:1:10,[43] with an empty mass of approximately 3.8 MDa.[44] The crystal structure of the VP3 protein was determined by Xie, Bue, et al.[45]

The cap gene produces an additional, non-structural protein called the Assembly-Activating Protein (AAP). This protein is produced from ORF2 and is essential for the capsid-assembly process.[46] The exact function of this protein in the assembly process and its structure have not been solved to date.

All three VPs are translated from one mRNA. After this mRNA is synthesized, it can be spliced in two different manners: either a longer or shorter intron can be excised resulting in the formation of two pools of mRNAs: a 2.3 kb- and a 2.6 kb-long mRNA pool. Usually, especially in the presence of adenovirus, the longer intron is preferred, so the 2.3-kb-long mRNA represents the so-called "major splice". In this form the first AUG codon, from which the synthesis of VP1 protein starts, is cut out, resulting in a reduced overall level of VP1 protein synthesis. The first AUG codon that remains in the major splice is the initiation codon for VP3 protein. However, upstream of that codon in the same open reading frame lies an ACG sequence (encoding threonine) which is surrounded by an optimal Kozak context. This contributes to a low level of synthesis of VP2 protein, which is actually VP3 protein with additional N terminal residues, as is VP1.[47] [48] [49] [50]

Since the bigger intron is preferred to be spliced out, and since in the major splice the ACG codon is a much weaker translation initiation signal, the ratio at which the AAV structural proteins are synthesized in vivo is about 1:1:20, which is the same as in the mature virus particle.[51] The unique fragment at the N terminus of VP1 protein was shown to possess the phospholipase A2 (PLA2) activity, which is probably required for the releasing of AAV particles from late endosomes.[52] Muralidhar et al. reported that VP2 and VP3 are crucial for correct virion assembly.[49] More recently, however, Warrington et al. showed VP2 to be unnecessary for the complete virus particle formation and an efficient infectivity, and also presented that VP2 can tolerate large insertions in its N terminus, while VP1 can not, probably because of the PLA2 domain presence.[53]

Post-translational modifications

Recent discoveries made through use of high-throughput 'omics approaches include the fact that AAV capsids are post-translationally modified (PTM) during production such as acetylation, methylation, phosphorylation, deamidation, O-GlycNAcylation[54] and SUMOylation throughout capsid proteins VP1, VP2 and VP3. These PTMs differ depending on the manufacturing production platform. Another such discovery is the fact that AAV genomes are epigenetically methylated during production. Besides price, these findings might affect expression kinetics, rAAV receptor binding, trafficking, vector immunogenicity, and expression durability.[55] [56]

Classification, serotypes, receptors and native tropism

in humans! Serotype !! Tissue tropism[57] !! Pass the blood brain barrier !! Cell tropism !! Synthetic !! Comment !! Published cap / rep
2 smooth muscle, CNS, liver
5 CNS, smooth muscle
8 CNS, Brain, Liver, smooth muscle
9 CNS, liver, smooth muscle
PAL2 CNS Liver expression is 1/4 of AAV9
9P1/AAVMYO CNS astrocytes high musculature including skeletal muscle, heart and diaphragmsckeletal transduction

Two species of AAV were recognised by the International Committee on Taxonomy of Viruses in 2013: adeno-associated dependoparvovirus A (formerly AAV-1, −2, −3 and −4) and adeno-associated dependoparvovirus B (formerly AAV-5).[58]

Until the 1990s, virtually all AAV biology was studied using AAV serotype 2. However, AAV is highly prevalent in humans and other primates and several serotypes have been isolated from various tissue samples. Serotypes 2, 3, 5, and 6 were discovered in human cells, AAV serotypes 1, 4, and 7–11 in nonhuman primate samples.[59] As of 2006 there have been 11 AAV serotypes described, the 11th in 2004.[60] AAV capsid proteins contain 12 hypervariable surface regions, with most variability occurring in the threefold proximal peaks, but the parvovirus genome in general presents highly conserved replication and structural genes across serotypes.[59] All of the known serotypes can infect cells from multiple diverse tissue types. Tissue specificity is determined by the capsid serotype and pseudotyping of AAV vectors to alter their tropism range will likely be important to their use in therapy.

Serotype 2

Serotype 2 (AAV2) has been the most extensively examined so far.[61] [62] [63] [64] [65] [66] AAV2 presents natural tropism towards skeletal muscles,[67] neurons,[61] vascular smooth muscle cells[68] and hepatocytes.[69]

Three cell receptors have been described for AAV2: heparan sulfate proteoglycan (HSPG), aVβ5 integrin and fibroblast growth factor receptor 1 (FGFR-1). The first functions as a primary receptor, while the latter two have a co-receptor activity and enable AAV to enter the cell by receptor-mediated endocytosis.[70] [71] [72] These study results have been disputed by Qiu, Handa, et al.[73] HSPG functions as the primary receptor, though its abundance in the extracellular matrix can scavenge AAV particles and impair the infection efficiency.[74]

Studies have shown that serotype 2 of the virus (AAV-2) apparently kills cancer cells without harming healthy ones. "Our results suggest that adeno-associated virus type 2, which infects the majority of the population but has no known ill effects, kills multiple types of cancer cells yet has no effect on healthy cells," said Craig Meyers,[75] a professor of immunology and microbiology at the Penn State College of Medicine in Pennsylvania in 2005.[76] This could lead to a new anti-cancer agent.

In March 2023, a series of Nature papers linked infection of adeno-associated virus 2 (AAV2) to a wave of childhood hepatitis.

Other serotypes

Although AAV2 is the most popular serotype in various AAV-based research, it has been shown that other serotypes can be more effective as gene delivery vectors. AAV9 passes the blood-brain-barrier in humans, AAV6 appears much better in infecting airway epithelial cells,[77] [78] AAV7 presents very high transduction rate of murine skeletal muscle cells (similar to AAV1 and AAV5), AAV8 transduce hepatocytes[79] [80] [81] and AAV1 and 5 were shown to be very efficient in gene delivery to vascular endothelial cells.[82] In the brain, most AAV serotypes show neuronal tropism, while AAV5 also transduces astrocytes.[83] AAV6, a hybrid of AAV1 and AAV2,[81] also shows lower immunogenicity than AAV2.[80]

Serotypes can differ with the respect to the receptors they are bound to. For example, AAV4 and AAV5 transduction can be inhibited by soluble sialic acids (of different form for each of these serotypes),[84] and AAV5 was shown to enter cells via the platelet-derived growth factor receptor.[85]

Synthetic serotypes

There have been many efforts to engineer and improve new AAV variants for both clinical and research purposes. Such modifications include new tropisms to target specific tissues, and modified surface residues to evade detection by the immune system. Beyond opting for particular strains of recombinant AAV (rAAV) to target particular cells, researchers have also explored AAV pseudotyping, the practice of creating hybrids of certain AAV strains to approach an even more refined target. The hybrid is created by taking a capsid from one strain and the genome from another strain. For example, research involving AAV2/5, a hybrid with the genome of AAV2 and the capsid of AAV5, was able to achieve more accuracy and range in brain cells than AAV2 would be able to achieve unhybridized. Researchers have continued to experiment with pseudotyping by creating strains with hybrid capsids. AAV-DJ has a hybrid capsid from eight different strains of AAV; as such, it can infect different cells throughout many areas of the body, a property which a single strain of AAV with a limited tropism would not have.[86] Other efforts to engineer and improve new AAV variants have involved the ancestral reconstruction of virus variants to generate new vectors with enhanced properties for clinical applications and the study of AAV biology.[87]

Immunology

AAV is of particular interest to gene therapists due to its apparent limited capacity to induce immune responses in humans, a factor which should positively influence vector transduction efficiency while reducing the risk of any immune-associated pathology.

AAV is not considered to have any known role in disease.[88] However, host immune system response and immune tolerance reduce the efficacy of AAV-mediated gene therapy. Host immune response has been shown to respond to the AAV vectors, the transduced cells, and the transduced proteins.[89] The immune response can be subdivided into two categories: innate and adaptive, the latter of which is divided into humoral and cell-mediated.[90] [91]

Innate

The innate immune response to the AAV vectors has been characterised in animal models. Intravenous administration in mice causes transient production of pro-inflammatory cytokines and some infiltration of neutrophils and other leukocytes into the liver, which seems to sequester a large percentage of the injected viral particles. Both soluble factor levels and cell infiltration appear to return to baseline within six hours. By contrast, more aggressive viruses produce innate responses lasting 24 hours or longer.[92]

In-vivo studies indicate that AAV vectors interact with the Toll-like receptor (TLR)9- and TLR2-MyD88 pathways to trigger the innate immune response by stimulating the production of interferons.[93] It's shown that mice deficient in TLR9 are more receptive to AAV treatment and demonstrate higher levels of transgene expression[94]

Humoral

Due to previous natural infection, many people have preexisting neutralizing antibodies (NAbs) against AAV's, which can significantly hinder its application in gene therapy.[95] Even though AAV's are highly variable among wild-type and synthetic variants, antibody recognition sites may be conserved evolutionarily.[96]

The virus is known to instigate robust humoral immunity in animal models and in the human population, where up to 80% of individuals are thought to be seropositive for AAV2. Antibodies are known to be neutralising, and for gene therapy applications these do impact vector transduction efficiency via some routes of administration. As well as persistent AAV specific antibody levels, it appears from both prime-boost studies in animals and from clinical trials that the B-cell memory is also strong.[97] In seropositive humans, circulating IgG antibodies for AAV2 appear to be primarily composed of the IgG1 and IgG2 subclasses, with little or no IgG3 or IgG4 present.

Cell-mediated

The cell-mediated response to the virus and to vectors is poorly characterised, and has been largely ignored in the literature as recently as 2005.[97] Clinical trials using an AAV2-based vector to treat haemophilia B seem to indicate that targeted destruction of transduced cells may be occurring.[98] Combined with data that shows that CD8+ T-cells can recognise elements of the AAV capsid in vitro,[99] it appears that there may be a cytotoxic T lymphocyte response to AAV vectors. Cytotoxic responses would imply the involvement of CD4+ T helper cells in the response to AAV and in vitro data from human studies suggests that the virus may indeed induce such responses, including both Th1 and Th2 memory responses.[100] A number of candidate T cell stimulating epitopes have been identified within the AAV capsid protein VP1, which may be attractive targets for modification of the capsid if the virus is to be used as a vector for gene therapy.[100] [98]

Infection cycle

There are several steps in the AAV infection cycle, from infecting a cell to producing new infectious particles:

  1. attachment to the cell membrane
  2. receptor-mediated endocytosis
  3. endosomal trafficking
  4. escape from the late endosome or lysosome
  5. translocation to the nucleus
  6. uncoating
  7. formation of double-stranded DNA replicative form of the AAV genome
  8. expression of rep genes
  9. genome replication
  10. expression of cap genes, synthesis of progeny ssDNA particles
  11. assembly of complete virions, and
  12. release from the infected cell.

Some of these steps may look different in various types of cells, which, in part, contributes to the defined and quite limited native tropism of AAV. Replication of the virus can also vary in one cell type, depending on the cell's current cell cycle phase.[101]

The characteristic feature of the adeno-associated virus is a deficiency in replication and thus its inability to multiply in unaffected cells. Adeno-associated virus spreads by co-infecting a cell with a helper virus. The first helper virus that was described as providing successful generation of new AAV particles, was the adenovirus, from which the AAV name originated. It was then shown that AAV replication can be facilitated by selected proteins derived from the adenovirus genome,[102] [103] by other viruses such as HSV[104] or vaccinia, or by genotoxic agents, such as UV irradiation or hydroxyurea.[105] [106] [107] Depending on the presence or absence of a helper virus, the life cycle of AAV follows either a lytic or lysogenic pathway, respectively.[108] If there is a helper virus, AAV's gene expression activates, allowing the virus to replicate using the host cell's polymerase. When the helper virus kills the host cell, the new AAV virions are released. If there is not a helper virus present, AAV exhibits lysogenic behavior. When AAV infects a cell alone, its gene expression is repressed (AAV does not replicate), and its genome is incorporated into the host genome (into human chromosome 19). In rare cases, lysis can occur without a helper virus, but usually AAV can not replicate and kill a cell on its own.[109]

The minimal set of the adenoviral genes required for efficient generation, of progeny AAV particles, was discovered by Matsushita, Ellinger et al.[102] This discovery allowed for new production methods of recombinant AAV, which do not require adenoviral co-infection of the AAV-producing cells. In the absence of helper virus or genotoxic factors, AAV DNA can either integrate into the host genome or persist in episomal form. In the former case integration is mediated by Rep78 and Rep68 proteins and requires the presence of ITRs flanking the region being integrated. In mice, the AAV genome has been observed persisting for long periods of time in quiescent tissues, such as skeletal muscles, in episomal form (a circular head-to-tail conformation).[110]

See also

External links

Notes and References

  1. Naso MF, Tomkowicz B, Perry WL, Strohl WR . Adeno-Associated Virus (AAV) as a Vector for Gene Therapy . BioDrugs . 31 . 4 . 317–334 . August 2017 . 28669112 . 5548848 . 10.1007/s40259-017-0234-5 .
  2. Wu Z, Yang H, Colosi P . Effect of genome size on AAV vector packaging . Molecular Therapy . 18 . 1 . 80–86 . January 2010 . 19904234 . 2839202 . 10.1038/mt.2009.255 .
  3. Book: Grieger JC, Samulski RJ . Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications . 99 . 119–45 . 2005 . 16568890 . 10.1007/10_005 . 978-3-540-28404-8 . Advances in Biochemical Engineering/Biotechnology . Adeno-associated Virus as a Gene Therapy Vector: Vector Development, Production and Clinical Applications .
  4. Deyle DR, Russell DW . Adeno-associated virus vector integration . Current Opinion in Molecular Therapeutics . 11 . 4 . 442–7 . August 2009 . 19649989 . 2929125 .
  5. Maguire AM, Simonelli F, Pierce EA, Pugh EN, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J . Safety and efficacy of gene transfer for Leber's congenital amaurosis . The New England Journal of Medicine . 358 . 21 . 2240–8 . May 2008 . 18441370 . 2829748 . 10.1056/NEJMoa0802315 .
  6. Tacke F . Severe hepatitis outbreak in children linked to AAV2 virus . Nature . 617 . 7961 . 471–472 . May 2023 . 36997704 . 10.1038/d41586-023-00570-8 . 2023Natur.617..471T .
  7. Servellita V, Sotomayor Gonzalez A, Lamson DM, Foresythe A, Huh HJ, Bazinet AL, Bergman NH, Bull RL, Garcia KY, Goodrich JS, Lovett SP, Parker K, Radune D, Hatada A, Pan CY, Rizzo K, Bertumen JB, Morales C, Oluniyi PE, Nguyen J, Tan J, Stryke D, Jaber R, Leslie MT, Lyons Z, Hedman HD, Parashar U, Sullivan M, Wroblewski K, Oberste MS, Tate JE, Baker JM, Sugerman D, Potts C, Lu X, Chhabra P, Ingram LA, Shiau H, Britt W, Gutierrez Sanchez LH, Ciric C, Rostad CA, Vinjé J, Kirking HL, Wadford DA, Raborn RT, St George K, Chiu CY . Adeno-associated virus type 2 in US children with acute severe hepatitis . Nature . 617 . 7961 . 574–580 . May 2023 . 36996871 . 10170441 . 10.1038/s41586-023-05949-1 . 2023Natur.617..574S .
  8. Carter BJ . Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective . Molecular Therapy . 10 . 6 . 981–9 . December 2004 . 15564130 . 10.1016/j.ymthe.2004.09.011 . free .
  9. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, McLaughlin S, Muzyczka N, Rocchi M, Berns KI . Site-specific integration by adeno-associated virus . Proceedings of the National Academy of Sciences of the United States of America . 87 . 6 . 2211–5 . March 1990 . 2156265 . 53656 . 10.1073/pnas.87.6.2211 . 1990PNAS...87.2211K . free .
  10. Surosky RT, Urabe M, Godwin SG, McQuiston SA, Kurtzman GJ, Ozawa K, Natsoulis G . Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome . Journal of Virology . 71 . 10 . 7951–9 . October 1997 . 9311886 . 192153 . 10.1128/JVI.71.10.7951-7959.1997 .
  11. Daya S, Berns KI . Gene therapy using adeno-associated virus vectors . Clinical Microbiology Reviews . 21 . 4 . 583–93 . October 2008 . 18854481 . 2570152 . 10.1128/CMR.00008-08 .
  12. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J . Immune responses to adenovirus and adeno-associated virus in humans . Gene Therapy . 6 . 9 . 1574–83 . Sep 1999 . 10490767 . 10.1038/sj.gt.3300994 . free .
  13. Hernandez YJ, Wang J, Kearns WG, Loiler S, Poirier A, Flotte TR . Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model . Journal of Virology . 73 . 10 . 8549–58 . October 1999 . 10482608 . 112875 . 10.1128/JVI.73.10.8549-8558.1999 .
  14. Ponnazhagan S, Mukherjee P, Yoder MC, Wang XS, Zhou SZ, Kaplan J, Wadsworth S, Srivastava A . Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice . Gene . 190 . 1 . 203–10 . April 1997 . 9185868 . 10.1016/S0378-1119(96)00576-8 .
  15. Bak RO, Porteus MH . CRISPR-Mediated Integration of Large Gene Cassettes Using AAV Donor Vectors . Cell Reports . 20 . 3 . 750–756 . July 2017 . 28723575 . 5568673 . 10.1016/j.celrep.2017.06.064 . Matthew Porteus .
  16. McCarty DM, Monahan PE, Samulski RJ . Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis . Gene Therapy . 8 . 16 . 1248–54 . August 2001 . 11509958 . 10.1038/sj.gt.3301514 . free .
  17. Rogers GL, Martino AT, Zolotukhin I, Ertl HC, Herzog RW . Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B . Journal of Translational Medicine . 12 . 25 . January 2014 . 24460861 . 3904690 . 10.1186/1479-5876-12-25 . free .
  18. Web site: Vectors used in Gene Therapy Clinical Trials . Journal of Gene Medicine . Wiley . 4 January 2012 . 21 October 2019 . https://web.archive.org/web/20191021212715/http://www.abedia.com/wiley/vectors.php . dead . December 2018 .
  19. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR . Effect of gene therapy on visual function in Leber's congenital amaurosis . The New England Journal of Medicine . 358 . 21 . 2231–9 . May 2008 . 18441371 . 10.1056/NEJMoa0802268 . 10.1.1.574.4003 .
  20. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, Conlon TJ, Boye SL, Flotte TR, Byrne BJ, Jacobson SG . Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial . Human Gene Therapy . 19 . 10 . 979–90 . October 2008 . 18774912 . 2940541 . 10.1089/hum.2008.107 .
  21. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM . Adenovirus-associated virus vector-mediated gene transfer in hemophilia B . The New England Journal of Medicine . 365 . 25 . 2357–65 . December 2011 . 22149959 . 10.1056/NEJMoa1108046 . 3265081.
  22. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ . Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure . Circulation . 124 . 3 . 304–13 . July 2011 . 21709064 . 5843948 . 10.1161/CIRCULATIONAHA.111.022889 .
  23. Web site: AveXis Reports Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1 . . 6 May 2016 . 8 May 2016 . https://web.archive.org/web/20170611055659/http://investors.avexis.com/phoenix.zhtml?c=254285&p=irol-newsArticle&ID=2166123 . 11 June 2017 . dead .
  24. Gaudet D, Méthot J, Déry S, Brisson D, Essiembre C, Tremblay G, Tremblay K, de Wal J, Twisk J, van den Bulk N, Sier-Ferreira V, van Deventer S . Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. . Gene Ther. . 20 . 4 . 361–9 . April 2013 . 22717743 . 10.1038/gt.2012.43 . 4956470 .
  25. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A . AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial . The Lancet. Neurology . 10 . 4 . 309–19 . April 2011 . 21419704 . 10.1016/S1474-4422(11)70039-4 . 37154043 .
  26. Carter BJ . Adeno-associated virus vectors in clinical trials . Human Gene Therapy . 16 . 5 . 541–50 . May 2005 . 15916479 . 10.1089/hum.2005.16.541 .
  27. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ . Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial . Lancet . 369 . 9579 . 2097–105 . June 2007 . 17586305 . 10.1016/S0140-6736(07)60982-9 . 24491886 .
  28. Book: Carter BJ . 2000 . Lassic DD, Templeton NS . 978-0-585-39515-9 . Adeno-associated virus and adeno-associated virus vectors for gene delivery . Gene Therapy: Therapeutic Mechanisms and Strategies . Marcel Dekker, Inc. . New York City . 41–59 .
  29. Bohenzky RA, LeFebvre RB, Berns KI . Sequence and symmetry requirements within the internal palindromic sequences of the adeno-associated virus terminal repeat . Virology . 166 . 2 . 316–27 . October 1988 . 2845646 . 10.1016/0042-6822(88)90502-8 .
  30. Wang XS, Ponnazhagan S, Srivastava A . Rescue and replication signals of the adeno-associated virus 2 genome . Journal of Molecular Biology . 250 . 5 . 573–80 . July 1995 . 7623375 . 10.1006/jmbi.1995.0398 .
  31. Weitzman MD, Kyöstiö SR, Kotin RM, Owens RA . Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA . Proceedings of the National Academy of Sciences of the United States of America . 91 . 13 . 5808–12 . June 1994 . 8016070 . 44086 . 10.1073/pnas.91.13.5808 . 1994PNAS...91.5808W . free .
  32. Zhou X, Muzyczka N . In vitro packaging of adeno-associated virus DNA . Journal of Virology . 72 . 4 . 3241–7 . April 1998 . 9525651 . 109794 . 10.1128/JVI.72.4.3241-3247.1998 .
  33. Nony P, Tessier J, Chadeuf G, Ward P, Giraud A, Dugast M, Linden RM, Moullier P, Salvetti A . Novel cis-acting replication element in the adeno-associated virus type 2 genome is involved in amplification of integrated rep-cap sequences . Journal of Virology . 75 . 20 . 9991–4 . October 2001 . 11559833 . 114572 . 10.1128/JVI.75.20.9991-9994.2001 .
  34. Nony P, Chadeuf G, Tessier J, Moullier P, Salvetti A . Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles . Journal of Virology . 77 . 1 . 776–81 . January 2003 . 12477885 . 140600 . 10.1128/JVI.77.1.776-781.2003 .
  35. Philpott NJ, Giraud-Wali C, Dupuis C, Gomos J, Hamilton H, Berns KI, Falck-Pedersen E . Efficient integration of recombinant adeno-associated virus DNA vectors requires a p5-rep sequence in cis . Journal of Virology . 76 . 11 . 5411–21 . June 2002 . 11991970 . 137060 . 10.1128/JVI.76.11.5411-5421.2002 .
  36. Tullis GE, Shenk T . Efficient replication of adeno-associated virus type 2 vectors: a cis-acting element outside of the terminal repeats and a minimal size . Journal of Virology . 74 . 24 . 11511–21 . December 2000 . 11090148 . 112431 . 10.1128/JVI.74.24.11511-11521.2000 .
  37. Kyöstiö SR, Owens RA, Weitzman MD, Antoni BA, Chejanovsky N, Carter BJ . Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels . Journal of Virology . 68 . 5 . 2947–57 . May 1994 . 8151765 . 236783 . 10.1128/JVI.68.5.2947-2957.1994 .
  38. Im DS, Muzyczka N . The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity . Cell . 61 . 3 . 447–57 . May 1990 . 2159383 . 10.1016/0092-8674(90)90526-K . 27997617 .
  39. Im DS, Muzyczka N . Partial purification of adeno-associated virus Rep78, Rep52, and Rep40 and their biochemical characterization . Journal of Virology . 66 . 2 . 1119–28 . February 1992 . 1309894 . 240816 . 10.1128/JVI.66.2.1119-1128.1992 .
  40. Book: Samulski RJ . Ernst Schering Research Foundation Workshop . AAV Vectors, the Future Workhorse of Human Gene Therapy . Human Gene Therapy: Current Opportunities and Future Trends . 43 . 25–40 . 2003 . 12894449 . 10.1007/978-3-662-05352-2_3 . 978-3-662-05354-6 .
  41. Trempe JP, Carter BJ . Regulation of adeno-associated virus gene expression in 293 cells: control of mRNA abundance and translation . Journal of Virology . 62 . 1 . 68–74 . January 1988 . 2824856 . 250502 . 10.1128/JVI.62.1.68-74.1988 .
  42. Jay FT, Laughlin CA, Carter BJ . Eukaryotic translational control: adeno-associated virus protein synthesis is affected by a mutation in the adenovirus DNA-binding protein . Proceedings of the National Academy of Sciences of the United States of America . 78 . 5 . 2927–31 . May 1981 . 6265925 . 319472 . 10.1073/pnas.78.5.2927 . 1981PNAS...78.2927J . free .
  43. Sonntag F, Schmidt K, Kleinschmidt JA . A viral assembly factor promotes AAV2 capsid formation in the nucleolus . Proceedings of the National Academy of Sciences of the United States of America . 107 . 22 . 10220–5 . June 2010 . 20479244 . 2890453 . 10.1073/pnas.1001673107 . 2010PNAS..10710220S . free .
  44. Pierson EE, Keifer DZ, Asokan A, Jarrold MF . Resolving Adeno-Associated Viral Particle Diversity With Charge Detection Mass Spectrometry . Analytical Chemistry . 88 . 13 . 6718–6725 . July 2016 . 27310298 . 6537880 . 10.1021/acs.analchem.6b00883 . American Chemical Society (ACS) .
  45. Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A, Chapman MS . The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy . Proceedings of the National Academy of Sciences of the United States of America . 99 . 16 . 10405–10 . August 2002 . 12136130 . 124927 . 10.1073/pnas.162250899 . 2002PNAS...9910405X . free .
  46. Sonntag F, Köther K, Schmidt K, Weghofer M, Raupp C, Nieto K, Kuck A, Gerlach B, Böttcher B, Müller OJ, Lux K, Hörer M, Kleinschmidt JA . The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes . Journal of Virology . 85 . 23 . 12686–97 . December 2011 . 21917944 . 3209379 . 10.1128/JVI.05359-11 .
  47. Becerra SP, Rose JA, Hardy M, Baroudy BM, Anderson CW . Direct mapping of adeno-associated virus capsid proteins B and C: a possible ACG initiation codon . Proceedings of the National Academy of Sciences of the United States of America . 82 . 23 . 7919–23 . December 1985 . 2999784 . 390881 . 10.1073/pnas.82.23.7919 . 1985PNAS...82.7919B . free .
  48. Cassinotti P, Weitz M, Tratschin JD . Organization of the adeno-associated virus (AAV) capsid gene: mapping of a minor spliced mRNA coding for virus capsid protein 1 . Virology . 167 . 1 . 176–84 . November 1988 . 2847413 . 10.1016/0042-6822(88)90067-0 .
  49. Muralidhar S, Becerra SP, Rose JA . Site-directed mutagenesis of adeno-associated virus type 2 structural protein initiation codons: effects on regulation of synthesis and biological activity . Journal of Virology . 68 . 1 . 170–6 . January 1994 . 8254726 . 236275 . 10.1128/JVI.68.1.170-176.1994 .
  50. Trempe JP, Carter BJ . Alternate mRNA splicing is required for synthesis of adeno-associated virus VP1 capsid protein . Journal of Virology . 62 . 9 . 3356–63 . September 1988 . 2841488 . 253458 . 10.1128/JVI.62.9.3356-3363.1988 .
  51. Rabinowitz JE, Samulski RJ . Building a better vector: the manipulation of AAV virions . Virology . 278 . 2 . 301–8 . December 2000 . 11118354 . 10.1006/viro.2000.0707 . free .
  52. Girod A, Wobus CE, Zádori Z, Ried M, Leike K, Tijssen P, Kleinschmidt JA, Hallek M . The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity . The Journal of General Virology . 83 . Pt 5 . 973–8 . May 2002 . 11961250 . 10.1099/0022-1317-83-5-973 . free .
  53. Warrington KH, Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N . Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus . Journal of Virology . 78 . 12 . 6595–609 . June 2004 . 15163751 . 416546 . 10.1128/JVI.78.12.6595-6609.2004 .
  54. Rumachik NG, Malaker SA, Poweleit N, Maynard LH, Adams CM, Leib RD, Ciriola G, Thomas D, Stamnes S, Holt K, Sinn P, May AP, Paulk NK . Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors . Molecular Therapy – Methods & Clinical Development . 18 . 98–118 . May 2020 . 32995354 . 7488757 . 10.1016/j.omtm.2020.05.018 .
  55. Chen Q, Njenga R, Leuchs B, Chiocca S, Kleinschmidt J, Muller M . SUMOylation Targets Adeno-associated Virus Capsids but Mainly Restricts Transduction by Cellular Mechanisms . Journal of Virology . 94 . 19 . e00871-20 . September 2020 . 32669341 . 7495375 . 10.1128/JVI.00871-20 .
  56. Giles AR, Sims JJ, Turner KB, Govindasamy L, Alvira MR, Lock M, Wilson JM . Deamidation of Amino Acids on the Surface of Adeno-Associated Virus Capsids Leads to Charge Heterogeneity and Altered Vector Function . Molecular Therapy . 26 . 12 . 2848–2862 . December 2018 . 30343890 . 6277538 . 10.1016/j.ymthe.2018.09.013 .
  57. Web site: AAV tropisms . VectorBuilder .
  58. Web site: Subfamily: Parvovirinae, Genus: Dependoparvovirus . International Committee on Taxonomy of Viruses (ICTV) . 31 January 2020 .
  59. Book: Weitzman MD, Linden RM . Snyder RO, Moullier P . Adeno-Associated Virus Biology . Adeno-associated virus methods and protocols . 2011 . Humana Press . Totowa, NJ . 978-1-61779-370-7.
  60. Mori S, Wang L, Takeuchi T, Kanda T . Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein . Virology . 330 . 2 . 375–83 . December 2004 . 15567432 . 10.1016/j.virol.2004.10.012 . free .
  61. Bartlett JS, Samulski RJ, McCown TJ . Selective and rapid uptake of adeno-associated virus type 2 in brain . Human Gene Therapy . 9 . 8 . 1181–6 . May 1998 . 9625257 . 10.1089/hum.1998.9.8-1181 .
  62. Fischer AC, Beck SE, Smith CI, Laube BL, Askin FB, Guggino SE, Adams RJ, Flotte TR, Guggino WB . Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques . Molecular Therapy . 8 . 6 . 918–26 . December 2003 . 14664794 . 10.1016/j.ymthe.2003.08.015 . free .
  63. Nicklin SA, Buening H, Dishart KL, de Alwis M, Girod A, Hacker U, Thrasher AJ, Ali RR, Hallek M, Baker AH . Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells . Molecular Therapy . 4 . 3 . 174–81 . September 2001 . 11545607 . 10.1006/mthe.2001.0424 . free .
  64. Rabinowitz JE, Xiao W, Samulski RJ . Insertional mutagenesis of AAV2 capsid and the production of recombinant virus . Virology . 265 . 2 . 274–85 . December 1999 . 10600599 . 10.1006/viro.1999.0045 . free .
  65. Shi W, Bartlett JS . RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism . Molecular Therapy . 7 . 4 . 515–25 . April 2003 . 12727115 . 10.1016/S1525-0016(03)00042-X . free .
  66. Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T, Flotte T, Muzyczka N . Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism . Journal of Virology . 74 . 18 . 8635–47 . September 2000 . 10954565 . 102071 . 10.1128/JVI.74.18.8635-8647.2000 .
  67. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni MV, Thompson A, Ozelo M, Couto LB, Leonard DG, Johnson FA, McClelland A, Scallan C, Skarsgard E, Flake AW, Kay MA, High KA, Glader B . AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B . Blood . 101 . 8 . 2963–72 . April 2003 . 12515715 . 10.1182/blood-2002-10-3296 . free .
  68. Richter M, Iwata A, Nyhuis J, Nitta Y, Miller AD, Halbert CL, Allen MD . Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo . Physiological Genomics . 2 . 3 . 117–27 . April 2000 . 11015590 . 10.1152/physiolgenomics.2000.2.3.117 . 14150468 .
  69. Koeberl DD, Alexander IE, Halbert CL, Russell DW, Miller AD . Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors . Proceedings of the National Academy of Sciences of the United States of America . 94 . 4 . 1426–31 . February 1997 . 9037069 . 19807 . 10.1073/pnas.94.4.1426 . 1997PNAS...94.1426K . free .
  70. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A . Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 . Nature Medicine . 5 . 1 . 71–7 . January 1999 . 9883842 . 10.1038/4758 . 31602526 .
  71. Summerford C, Samulski RJ . Membrane-associated heparan sulfate proteo-glycan is a receptor for adeno-associated virus type 2 virions . Journal of Virology . 72 . 2 . 1438–45 . Feb 1998 . 9445046 . 124624 . 10.1128/JVI.72.2.1438-1445.1998 .
  72. Summerford C, Bartlett JS, Samulski RJ . AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection . Nature Medicine . 5 . 1 . 78–82 . January 1999 . 9883843 . 10.1038/4768 . 23326070 .
  73. Qiu J, Handa A, Kirby M, Brown KE . The interaction of heparin sulfate and adeno-associated virus 2 . Virology . 269 . 1 . 137–47 . March 2000 . 10725206 . 10.1006/viro.2000.0205 . free .
  74. Pajusola K, Gruchala M, Joch H, Lüscher TF, Ylä-Herttuala S, Büeler H . Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells . Journal of Virology . 76 . 22 . 11530–40 . November 2002 . 12388714 . 136795 . 10.1128/JVI.76.22.11530-11540.2002 .
  75. News: 22 June 2005 . Common virus 'kills cancer' . CNN. 5 August 2009 .
  76. Web site: Penn State . Harmless Virus Kills Some Cancers . 23 June 2005 . Science Daily .
  77. Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM . Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro . Molecular Therapy . 17 . 2 . 294–301 . February 2009 . 19066597 . 2835069 . 10.1038/mt.2008.261 .
  78. Strobel B, Duechs MJ, Schmid R, Stierstorfer BE, Bucher H, Quast K, Stiller D, Hildebrandt T, Mennerich D, Gantner F, Erb KJ, Kreuz S . Modeling Pulmonary Disease Pathways Using Recombinant Adeno-Associated Virus 6.2 . American Journal of Respiratory Cell and Molecular Biology . 53 . 3 . 291–302 . September 2015 . 25845025 . 10.1165/rcmb.2014-0338MA .
  79. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM . Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy . Proceedings of the National Academy of Sciences of the United States of America . 99 . 18 . 11854–9 . September 2002 . 12192090 . 129358 . 10.1073/pnas.182412299 . 2002PNAS...9911854G . free .
  80. Halbert CL, Allen JM, Miller AD . Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors . Journal of Virology . 75 . 14 . 6615–24 . July 2001 . 11413329 . 114385 . 10.1128/JVI.75.14.6615-6624.2001 .
  81. Rabinowitz JE, Bowles DE, Faust SM, Ledford JG, Cunningham SE, Samulski RJ . Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups . Journal of Virology . 78 . 9 . 4421–32 . May 2004 . 15078923 . 387689 . 10.1128/JVI.78.9.4421-4432.2004 .
  82. Chen S, Kapturczak M, Loiler SA, Zolotukhin S, Glushakova OY, Madsen KM, Samulski RJ, Hauswirth WW, Campbell-Thompson M, Berns KI, Flotte TR, Atkinson MA, Tisher CC, Agarwal A . Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors . Human Gene Therapy . 16 . 2 . 235–47 . February 2005 . 15761263 . 1364465 . 10.1089/hum.2005.16.235 .
  83. Ortinski PI, Dong J, Mungenast A, Yue C, Takano H, Watson DJ, Haydon PG, Coulter DA . Selective induction of astrocytic gliosis generates deficits in neuronal inhibition . Nature Neuroscience . 13 . 5 . 584–91 . May 2010 . 20418874 . 3225960 . 10.1038/nn.2535 .
  84. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA . Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity . Journal of Virology . 75 . 15 . 6884–93 . August 2001 . 11435568 . 114416 . 10.1128/JVI.75.15.6884-6893.2001 .
  85. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA . Identification of PDGFR as a receptor for AAV-5 transduction . Nature Medicine . 9 . 10 . 1306–12 . October 2003 . 14502277 . 10.1038/nm929 . 32547188 .
  86. Web site: Adeno-associated Virus (AAV) Guide . Addgene . Watertown, MA .
  87. Zinn E, Pacouret S, Khaychuk V, Turunen HT, Carvalho LS, Andres-Mateos E, Shah S, Shelke R, Maurer AC, Plovie E, Xiao R, Vandenberghe LH . In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector . Cell Reports . 12 . 6 . 1056–68 . August 2015 . 26235624 . 10.1016/j.celrep.2015.07.019 . 4536165.
  88. Flotte TR, Berns KI . Adeno-associated virus: a ubiquitous commensal of mammals . Human Gene Therapy . 16 . 4 . 401–407 . April 2005 . 15871671 . 10.1089/hum.2005.16.401 .
  89. Ronzitti G, Gross DA, Mingozzi F . Human Immune Responses to Adeno-Associated Virus (AAV) Vectors . Frontiers in Immunology . 11 . 670 . 2020 . 32362898 . 7181373 . 10.3389/fimmu.2020.00670 . free .
  90. Vandamme C, Adjali O, Mingozzi F . Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial . Human Gene Therapy . 28 . 11 . 1061–1074 . November 2017 . 28835127 . 5649404 . 10.1089/hum.2017.150 .
  91. Barnes C, Scheideler O, Schaffer D . Engineering the AAV capsid to evade immune responses . Current Opinion in Biotechnology . 60 . 99–103 . December 2019 . 30807882 . 7117822 . 10.1016/j.copbio.2019.01.002 .
  92. Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA . Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors . Journal of Virology . 76 . 9 . 4580–90 . May 2002 . 11932423 . 155101 . 10.1128/JVI.76.9.4580-4590.2002 .
  93. Zhu J, Huang X, Yang Y . The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice . The Journal of Clinical Investigation . 119 . 8 . 2388–2398 . August 2009 . 19587448 . 2719948 . 10.1172/JCI37607 .
  94. Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B, Ertl HC, Muruve DA, Lee B, Herzog RW . The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver . Blood . 117 . 24 . 6459–6468 . June 2011 . 21474674 . 3123017 . 10.1182/blood-2010-10-314518 .
  95. Calcedo R, Morizono H, Wang L, McCarter R, He J, Jones D, Batshaw ML, Wilson JM . Adeno-associated virus antibody profiles in newborns, children, and adolescents . Clinical and Vaccine Immunology . 18 . 9 . 1586–1588 . September 2011 . 21775517 . 3165215 . 10.1128/CVI.05107-11 .
  96. Tse LV, Klinc KA, Madigan VJ, Castellanos Rivera RM, Wells LF, Havlik LP, Smith JK, Agbandje-McKenna M, Asokan A . Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion . Proceedings of the National Academy of Sciences of the United States of America . 114 . 24 . E4812-E4821 . June 2017 . 28559317 . 5474820 . 10.1073/pnas.1704766114 . free . 2017PNAS..114E4812T .
  97. Zaiss AK, Muruve DA . Immune responses to adeno-associated virus vectors . Current Gene Therapy . 5 . 3 . 323–31 . June 2005 . 15975009 . 10.2174/1566523054065039 .
  98. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Rasko J, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA . Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response . Nature Medicine . 12 . 3 . 342–7 . March 2006 . 16474400 . 10.1038/nm1358 . 14664182 .
  99. Sabatino DE, Mingozzi F, Hui DJ, Chen H, Colosi P, Ertl HC, High KA . Identification of mouse AAV capsid-specific CD8+ T cell epitopes . Molecular Therapy . 12 . 6 . 1023–33 . December 2005 . 16263332 . 10.1016/j.ymthe.2005.09.009 . free .
  100. Madsen D, Cantwell ER, O'Brien T, Johnson PA, Mahon BP . Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1 . The Journal of General Virology . 90 . Pt 11 . 2622–33 . November 2009 . 19641045 . 2885037 . 10.1099/vir.0.014175-0 .
  101. Rohr UP, Kronenwett R, Grimm D, Kleinschmidt J, Haas R . Primary human cells differ in their susceptibility to rAAV-2-mediated gene transfer and duration of reporter gene expression . Journal of Virological Methods . 105 . 2 . 265–75 . September 2002 . 12270659 . 10.1016/S0166-0934(02)00117-9 .
  102. Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ, Iwaki Y, Colosi P . Adeno-associated virus vectors can be efficiently produced without helper virus . Gene Therapy . 5 . 7 . 938–45 . July 1998 . 9813665 . 10.1038/sj.gt.3300680 . free .
  103. Myers MW, Laughlin CA, Jay FT, Carter BJ . Adenovirus helper function for growth of adeno-associated virus: effect of temperature-sensitive mutations in adenovirus early gene region 2 . Journal of Virology . 35 . 1 . 65–75 . July 1980 . 6251278 . 288783 . 10.1128/JVI.35.1.65-75.1980 .
  104. Handa H, Carter BJ . Adeno-associated virus DNA replication complexes in herpes simplex virus or adenovirus-infected cells . The Journal of Biological Chemistry . 254 . 14 . 6603–10 . July 1979 . 10.1016/S0021-9258(18)50411-7 . 221504 . free .
  105. Yalkinoglu AO, Heilbronn R, Bürkle A, Schlehofer JR, zur Hausen H . DNA amplification of adeno-associated virus as a response to cellular genotoxic stress . Cancer Research . 48 . 11 . 3123–9 . June 1988 . 2835153 .
  106. Yakobson B, Koch T, Winocour E . Replication of adeno-associated virus in synchronized cells without the addition of a helper virus . Journal of Virology . 61 . 4 . 972–81 . April 1987 . 3029431 . 254052 . 10.1128/JVI.61.4.972-981.1987 .
  107. Yakobson B, Hrynko TA, Peak MJ, Winocour E . Replication of adeno-associated virus in cells irradiated with UV light at 254 nm . Journal of Virology . 63 . 3 . 1023–30 . March 1989 . 2536816 . 247794 . 10.1128/JVI.63.3.1023-1030.1989 .
  108. Web site: Introduction to Adeno-Associated Virus (AAV) . Vector Biolabs . Malvern, PA .
  109. Web site: Adeno-Associated Virus and Adeno-associated Viral Vectors . 19 September 2018 . https://web.archive.org/web/20180920045917/https://ehs.research.uiowa.edu/adeno-associated-virus-and-adeno-associated-viral-vectors . 20 September 2018 . dead . Environmental Health & Safety . University of Iowa .
  110. Duan D, Sharma P, Yang J, Yue Y, Dudus L, Zhang Y, Fisher KJ, Engelhardt JF . Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue . Journal of Virology . 72 . 11 . 8568–77 . November 1998 . 9765395 . 110267 . 10.1128/JVI.72.11.8568-8577.1998 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Adeno-associated virus".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.